Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.

about

Case of relentless chronic phase of chronic myeloid leukaemia.

P2860

Q51686970-FC9529E2-395C-488F-8973-515E7A25F900

P2860

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.

Item

http://www.wikidata.org/entity/Q38685803

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Considering baseline factors a ...... oid leukemia in chronic phase.

@en

type

Item

label

Considering baseline factors a ...... oid leukemia in chronic phase.

@en

prefLabel

Considering baseline factors a ...... oid leukemia in chronic phase.

@en

P1476

Considering baseline factors a ...... oid leukemia in chronic phase.

@en

P2093

Dale Bixby

http://www.w3.org/2001/XMLSchema#string

Luke P Akard

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

P304

1002-1014

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1122779

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26726949

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.

about

P2860

P2860

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921